



Health Care and Disease Management

# Prevention of Fetal Alcohol Spectrum Disorder FASD

Who is Responsible?

Edited by Sterling Clarren,  
Amy Salmon, and Egon Jonsson

IHE

INSTITUTE OF  
HEALTH ECONOMICS  
ALBERTA CANADA



WILEY-  
BLACKWELL



*Edited by*  
*Sterling Clarren,*  
*Amy Salmon, and*  
*Egon Jonsson*

**Prevention of Fetal Alcohol  
Spectrum Disorder FASD**

## *Titles of the series “Health Care and Disease Management”*

Riley, E.P., Clarren, S., Weinberg, J.,  
Jonsson, E. (eds.)

### **Fetal Alcohol Spectrum Disorder**

**Management and Policy  
Perspectives of FASD**

2011  
978-3-527-32839-0

Martin, W., Suchowersky, O.,  
Kovacs Burns, K., Jonsson, E. (eds.)

### **Parkinson Disease A Health Policy Perspective**

2010  
ISBN: 978-3-527-32779-9

Rapoport, J., Jacobs, P., Jonsson, E. (eds.)

### **Cost Containment and Efficiency in National Health Systems**

**A Global Comparison**

2009  
ISBN: 978-3-527-32110-0

Rashiq, S., Schopflocher, D.,  
Taenzer, P., Jonsson, E. (eds.)

### **Chronic Pain A Health Policy Perspective**

2008  
ISBN: 978-3-527-32382-1

Lu, M., Jonsson, E. (eds.)

### **Financing Health Care New Ideas for a Changing Society**

2008  
ISBN: 978-3-527-32027-1

## ***Related Titles***

Riley, E.P., Clarren, S., Weinberg, J.,  
Jonsson, E. (eds.)

### **Fetal Alcohol Spectrum Disorder**

**Management and Policy Perspectives  
of FASD**

2011  
978-3-527-32839-0

Miller, N.S., Gold, M.S. (eds.)

### **Addictive Disorders in Medical Populations**

2010  
ISBN: 978-0-470-74033-0

Mitcheson, L., Maslin, J., Meynen, T.,  
Morrison, T., Hill, R., Wanigaratne, S.,  
Padesky, C.A. (Foreword by)

### **Applied Cognitive and Behavioural Approaches to the Treatment of Addiction: A Practical Treatment Guide**

2010  
ISBN: 978-0-470-51062-9

*Edited by Sterling Clarren, Amy Salmon, and Egon Jonsson*

## **Prevention of Fetal Alcohol Spectrum Disorder FASD**

Who is responsible?

 **WILEY-BLACKWELL**

## The Editors

### **Prof. Sterling Clarren**

University of British Columbia  
Faculty of Medicine  
L408–4480 Oak Street  
Vancouver, BC V6H 3V4  
Canada

### **Dr. Amy Salmon**

University of British Columbia  
Faculty of Medicine  
E202–4500 Oak Street  
Vancouver, BC V6H 3N1  
Canada

### **Prof. Dr. Egon Jonsson**

University of Calgary  
Department of Public  
Health Sciences  
CEO Institute of Health  
Economics  
1200 10405 Jasper Avenue  
Edmonton, AB T5J 3N4  
Canada

## Series Editor

### **Prof. Dr. Egon Jonsson**

University of Calgary  
Department of Public  
Health Sciences  
Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton, AB T5J 3N4  
Canada

## Cover

Oil painting on canvas by  
Egon Jonsson

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

**Library of Congress Card No.:** applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2011 Wiley-VCH Verlag & Co. KGaA,  
Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Typesetting** Toppan Best-set Premedia Limited,  
Hong Kong

**Printing and Binding** betz-druck GmbH, Darmstadt

**Cover Design** Adam-Design, Weinheim

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**ISBN Print:** 978-3-527-32997-7

**ISBN eBook:** 978-3-527-63548-1

**ISBN ePDF:** 978-3-527-63550-4

**ISBN ePub:** 978-3-527-63549-8

**ISBN Mobi:** 978-3-527-63551-1

**ISSN:** 1864-9947

## Contents

**Preface** XI

**List of Contributors** XIII

<b>1</b>	<b>Introduction</b>	<b>1</b>
	<i>Sterling Clarren, Amy Salmon, and Egon Jonsson</i>	
1.1	The Content of This Book	2
1.2	What is FASD?	4
1.3	How Common is FASD?	5
1.4	What is the Economic Burden of FASD?	6
1.4.1	Annual Cost Per Person with FASD	6
1.4.2	Comparing Costs	7
1.4.3	Cost of Prevention versus Cost of Inaction	8
1.5	Approaches to FASD Prevention	9
1.5.1	Universal Prevention	9
1.5.2	Screening for Prenatal Alcohol Exposure in Obstetric Settings	11
1.5.2.1	Meconium Testing	12
1.5.2.2	Maternal Self-Reporting	12
1.5.3	Selective Prevention	13
1.5.4	Indicated Prevention	14
1.6	FASD Prevention in Aboriginal Communities	16
1.7	Main obstacles to Preventing FASD	17
1.8	Challenges in Measuring Effectiveness of FASD Prevention Initiatives	18
1.9	Who is Responsible for the Prevention of FASD?	19
	References	21
<b>2</b>	<b>An Overview of Systematic Reviews on the Prevention, Diagnosis, and Treatment of Fetal Alcohol Spectrum Disorder</b>	<b>27</b>
	<i>Maria Ospina, Carmen Moga, Liz Dennett, and Christa Harstall</i>	
2.1	Introduction	32
2.2	Objective and Scope	34
2.3	Methodological Approach	34
2.3.1	Elements of Assessment	34

2.4	Results	35
2.4.1	Search Results	35
2.4.1.1	Characteristics of Systematic Reviews Included in the Overview	36
2.4.2	Systematic Reviews on Prevention of FASD and Prenatal Alcohol Use	37
2.4.2.1	General Characteristics	37
2.4.2.2	Methodological Characteristics of Systematic Reviews on Prevention of FASD and Prenatal Alcohol Use	40
2.4.3	Methodological Quality of Systematic Reviews on Prevention of FASD and Prenatal Alcohol Use	42
2.4.3.1	Characteristics of the Evidence Presented in the Systematic Reviews on Prevention Approaches to FASD and Prenatal Alcohol Use	43
2.4.3.2	Qualitative Synthesis of the Evidence on the Effectiveness of Prevention Approaches to FASD and Prenatal Alcohol Use	44
2.4.3.3	Highlights of the Overall Results	51
2.4.4	Systematic Reviews on the Diagnosis of FASD	54
2.4.4.1	General Characteristics	54
2.4.4.2	Methodological Characteristics of the Systematic Review on Diagnosis of FASD	55
2.4.4.3	Methodological Quality of Systematic Reviews on Diagnosis of FASD	55
2.4.4.4	Characteristics of the Evidence Presented in the Systematic Review on the Effectiveness of Diagnostic Approaches to FASD	56
2.4.4.5	Qualitative Synthesis of the Evidence on the Effectiveness of Diagnostic Approaches to FASD	57
2.4.4.6	Highlights of the Overall Results	59
2.4.5	Systematic Reviews on the Treatment of FASD	59
2.4.5.1	General Characteristics	59
2.4.5.2	Methodological Characteristics of Systematic Reviews on Therapeutic Approaches to FASD	61
2.4.5.3	Methodological Quality of Systematic Reviews on Therapeutic Approaches to FASD	62
2.4.5.4	Characteristics of the Evidence Presented in the Systematic Reviews on Therapeutic Approaches to FASD	62
2.4.5.5	Qualitative Synthesis of the Evidence on the Effectiveness of Therapeutic Approaches to FASD	64
2.4.5.6	Highlights of the Overall Results	69
2.5	Discussion	69
2.5.1	FASD Prevention	71
2.5.2	FASD Diagnosis	72
2.5.3	FASD Treatment	73
2.5.4	Methodological Quality of the Overview of Systematic Reviews	73
2.5.4.1	Strengths and Limitations	73
2.6	Conclusions	74
	Appendix 2.A: Methodology	74



Search Strategy	74
Study Selection Process	74
Data Extraction	78
Methodological Quality Assessment	78
Data Analysis and Synthesis of the Results	81
Appendix 2.B: Excluded Studies and Multiple Publications	81
Excluded Research Studies	81
Multiple Publications of Studies Included in the Review	83
Appendix 2.C: Summary Tables of Overall Characteristics of Systematic Reviews on Prevention, Diagnosis, and Treatment of FASD	84
Appendix 2.D: Methodological Quality of Systematic Reviews Included in the Overview	93
References	96

### **3 A Systematic Review of the Effectiveness of Prevention Approaches for Fetal Alcohol Spectrum Disorder 99**

*Maria Ospina, Carmen Moga, Liz Dennett, and Christa Harstall*

3.1	Introduction	105
3.2	Objective and Scope	108
3.3	Methodological Approach	108
3.3.1	Elements of Assessment	108
3.4	Studies on the Effectiveness of FASD Preventive Approaches	109
3.4.1	Search Results	109
3.4.2	Characteristics of Included Studies	110
3.4.2.1	General Characteristics	110
3.4.2.2	Characteristics of the Populations	111
3.4.2.3	Characteristics of the Interventions	112
3.4.2.4	Components of the Interventions	113
3.4.2.5	Characteristics of the Outcomes	115
3.4.2.6	Types of Result Reported in the Individual Studies	115
3.4.3	Methodological Quality of the Studies	118
3.4.4	Highlights of the Overall Results	119
3.4.4.1	Populations	120
3.4.4.2	Interventions	120
3.4.4.3	Outcomes	120
3.4.4.4	Methodological Quality	121
3.5	Evidence on the Effectiveness of Universal Prevention Approaches for FASD	121
3.5.1	Characteristics of Included Studies	121
3.5.1.1	General Characteristics	121
3.5.1.2	Characteristics of the Populations	122
3.5.1.3	Characteristics of the Interventions	122
3.5.1.4	Components of the Interventions	125
3.5.1.5	Characteristics of the Outcomes	125

3.5.1.6	Types of Result Reported in the Individual Studies	125
3.5.2	Methodological Quality of the Studies	128
3.5.3	Results of Qualitative Synthesis of the Evidence	130
3.5.3.1	Clinical Trials	130
3.5.3.2	Observational Studies	131
3.5.4	Summary of the Overall Results	137
3.5.4.1	General Characteristics	137
3.5.4.2	Populations	137
3.5.4.3	Interventions	137
3.5.4.4	Outcomes	137
3.5.4.5	Methodological Quality of the Studies	138
3.5.4.6	Evidence on the Effectiveness of Universal Prevention Approaches	138
3.6	Evidence on the Effectiveness of Selective Prevention Approaches for FASD	145
3.6.1	Characteristics of Included Studies	145
3.6.1.1	General Characteristics	145
3.6.1.2	Characteristics of the Populations	145
3.6.1.3	Characteristics of the Interventions	146
3.6.1.4	Components of the Interventions	147
3.6.1.5	Characteristics of the Outcomes	149
3.6.1.6	Types of Result Reported in the Individual Studies	149
3.6.2	Methodological Quality of the Studies	152
3.6.3	Results of Qualitative Synthesis of the Evidence	154
3.6.3.1	Clinical Trials	154
3.6.3.2	Observational Studies	161
3.6.4	Summary of the Overall Results	164
3.6.4.1	General Characteristics	164
3.6.4.2	Populations	165
3.6.4.3	Interventions	165
3.6.4.4	Outcomes	165
3.6.4.5	Methodological Quality of the Studies	165
3.6.4.6	Evidence on the Effectiveness of Selective Prevention Approaches	165
3.7	Evidence on the Effectiveness of Indicated Prevention Approaches for FASD	173
3.7.1	Characteristics of Included Studies	173
3.7.1.1	General Characteristics	173
3.7.1.2	Characteristics of the Populations	174
3.7.1.3	Characteristics of the Interventions	174
3.7.1.4	Components of the Interventions	175
3.7.1.5	Characteristics of the Outcomes	176
3.7.1.6	Types of Result Reported in the Individual Studies	178
3.7.2	Methodological Quality of the Studies	178

3.7.3	Results of Qualitative Synthesis of the Evidence	180
3.7.3.1	Clinical Trials	181
3.7.3.2	Observational Studies	182
3.7.4	Summary of the Overall Results	184
3.7.4.1	General Characteristics	184
3.7.4.2	Populations	185
3.7.4.3	Interventions	185
3.7.4.4	Outcomes	185
3.7.4.5	Methodological Quality of the Studies	185
3.7.4.6	Evidence on the Effectiveness of Indicated Prevention Approaches	185
3.7.5	Analysis of Publication Bias	189
3.8	Discussion	189
3.8.1	Characteristics of the Study Populations	189
3.8.2	Characteristics of the Interventions	191
3.8.3	Characteristics of Study Outcomes	191
3.8.4	Methodological Quality of the Studies	192
3.8.5	Main Findings	193
3.8.6	Universal Prevention Approaches	193
3.8.7	Selective Prevention Approaches	194
3.8.8	Indicated Prevention Approaches	195
3.8.9	Strengths and Limitations	195
3.8.10	Methodological Issues and Research Directions in the Evaluation of FASD Prevention Interventions	196
3.9	Conclusions	198
	Acknowledgments	199
	Competing Interest	200
	Appendix 3.A: Methodology	200
	Search Strategy	200
	Study Selection Process	207
	Data Extraction	208
	Methodological Quality Assessment	208
	Data Analysis and Synthesis of the Results	213
	Appendix 3.B: Excluded Studies, Multiple Publications and Studies Pending Full Publication	213
	Excluded Research Studies	213
	Multiple Publications of Studies Included in the Review	222
	Studies Pending Full Publication	223
	Appendix 3.C: Summary Tables of Overall Characteristics of Studies on Prevention Approaches to FASD	224
	Appendix 3.D: Operational Definitions of Prevention Approaches to FASD	235
	Appendix 3.E: Study Evidence Tables	240
	Appendix 3.F: Characteristics of the Interventions	304

Appendix 3.G: Methodological Quality of the Studies Included in  
the Review 320  
References 330

**4 Five Perspectives on Prevention of FASD 337**  
*Lola Baydala, Robin Thurmeier, June Bergman, Nancy Whitney,  
and Amy Salmon*

4.1 Pre-Conception Initiatives 337  
4.2 Inventory of Primary Prevention Campaigns 340  
4.3 Primary Care Physician Perspective 343  
4.4 Mentoring Programs for At-Risk Mothers 345  
PCAP Studies Cited 350  
4.5 Strength and Support: A Women’s Perspective 350  
4.5.1 Recommendations 356  
References 357

**Appendices 359**  
Abbreviations 359  
Glossary 360  
References 364

**Index 365**

## Preface

Research has well established that alcohol consumption during pregnancy may cause serious and irreversible brain damage to the fetus. Nobody would think of giving alcohol to a toddler; nevertheless, at least one in every 100 babies is born with a lifelong disorder resulting from the effects of fetal alcohol exposure. Fetal alcohol spectrum disorder—or FASD—is devastating for both the individual and the family, and its prevention is considered to be a high public health priority in many jurisdictions.

This book reviews evidence from research on the effectiveness of various strategies for the prevention of FASD. Considerable doubt continues to be raised about the effectiveness of some of the most commonly used prevention strategies, such as public media campaigns and printed information about the harm of alcohol use during pregnancy, as well as prenatal programs that educate pregnant women about the risks of drinking but do not address the root causes of drinking. There is, however, evidence that intensive interventions and other types of targeted support for high-risk mothers are both effective and cost-effective.

Every year, thousands of children are born with permanent brain injury resulting from exposure to alcohol during gestation. The response to that should be a forceful, determined, and sustainable effort to prevent this situation from occurring. It seems reasonable to suggest, therefore, that current approaches to prevention of FASD need to be reconsidered, and that a reallocation of resources to strategies that have a proven effectiveness should become a priority. Moreover, concerted efforts must be given to the development of new strategies for preventing this disorder.

But, who will take responsibility for FASD prevention? FASD falls across many areas of potential responsibility. It does not have a home in any particular specialty of medicine—its implications are shared by ministries of health, education, children, and social services. To some extent, it also concerns departments and institutions responsible for correctional services, since individuals with FASD seems to be disproportionately represented among those in conflict with the justice system.

We argue that provincial, national, and international bodies need to work together to develop the multisectoral strategies required for the effective prevention of FASD. Moreover, we believe that the World Health Organization, in

collaboration with member states, should take the initiative in formulating priorities in research and policy development for the prevention of FASD—in addition to its more general global strategy to reduce harmful use of alcohol.

Vancouver and Edmonton, February 2011

*Sterling Clarren*

*Amy Salmon*

*Egon Jonsson*

*Note from the editors:* This is the second of two books on FASD produced by the Institute of Health Economics in Edmonton, Canada, and published by Wiley-Blackwell. The first book, which focuses on FASD in a policy and management perspective, also contains several chapters that relate to the prevention of FASD (see *Fetal Alcohol Spectrum Disorder: Management and Policy Perspectives of FASD*, by Riley, E.P., Clarren, S., Weinberg, J., and Jonsson, E., Wiley-Blackwell, 2011, ISBN 978-3-527-32839-0).

## List of Contributors

### ***Lola Baydala***

University of Alberta  
Faculty of Medicine and Dentistry  
Department of Pediatrics  
87 Avenue  
Edmonton  
Alberta T5R 4H5  
Canada

### ***June Bergman***

University of Alberta  
Faculty of Medicine and Dentistry  
Department of Pediatrics  
87 Avenue  
Edmonton  
Alberta T5R 4H5  
Canada

### ***Sterling Clarren***

Canada Northwest FASD Research  
Network  
L 408–4480 Oak Street  
Vancouver  
British Columbia V6H 3V4  
Canada

### ***Liz Dennett***

University of Calgary  
Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton  
Alberta T5J 3N4  
Canada

### ***Christa Harstall***

University of Calgary  
Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton  
Alberta T5J 3N4  
Canada

### ***Egon Jonsson***

University of Calgary  
Department of Public  
Health Sciences  
Executive Director & CEO  
Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton  
Alberta T5J 3N4  
Canada

### ***Carmen Moga***

University of Calgary  
Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton  
Alberta T5J 3N4  
Canada

***Maria Ospina***

Institute of Health Economics  
1200 10405 Jasper Avenue  
Edmonton  
Alberta T5J 3N4  
Canada

***Amy Salmon***

University of British Columbia  
Faculty of Medicine  
School of Population and Public  
Health, and Canada Northwest FASD  
Research Network  
E202–4500 Oak Street  
Vancouver  
British Columbia V6H 3N1  
Canada

***Robin Thurmeier***

University of Calgary  
University of Regina  
Faculty of Business Administration  
1918 Cairns Avenue  
Saskatoon  
Saskatchewan S7J 1T4  
Canada

***Nancy Whitney***

University of Washington  
King County Parent-Child Assistance  
Program  
Psychiatry and Behavioral Sciences  
650 S. Orcas Street 103  
Seattle WA 98108  
USA



## 1

**Introduction**

*Sterling Clarren, Amy Salmon, and Egon Jonsson*

This book is about the prevention of a disability that does not need to exist: fetal alcohol spectrum disorder (FASD). Alcohol use during pregnancy is the direct cause of this disability, which the baby must live with for the rest of its life. The damage caused to the brain of the fetus by exposure to alcohol is irreparable. Who is responsible for this?

For almost 40 years, FASD has been said to be entirely preventable, and ever since the cause of the disorder was established, women who drink while they are pregnant have been made to feel fully responsible for perpetuating this “entirely preventable” condition. But, the more we learn about FASD and the challenges to its prevention, the more we realize that investing only pregnant women with the responsibility for FASD prevention is misguided, ineffective, and punitive. Yet, if the responsibility for FASD prevention does not lie only with women who drink when they are pregnant, who else is responsible?

That question is not as easy to answer as it may seem, since there are many reasons for alcohol use during pregnancy. Men who are violent at home, who abuse alcohol themselves and who encourage or demand their pregnant partner to drink with them are responsible for the syndrome. The social determinants of health, such as poverty, poor housing, poor nutrition, along with other complicating social circumstances, may also be implicated in the alcohol use that causes FASD. Healthcare and social service providers who fail not only to ask pregnant women about their alcohol use but also to provide meaningful support to women at risk, may be seen as responsible. Governments who do not adequately fund the programs, services, and infrastructure necessary for providers to reach families who are struggling also hold responsibility for FASD.

Pregnant women who drink are, of course, also responsible. Some women drink before they know that they are pregnant; some may believe that only heavy drinking will endanger their baby, and that consuming a moderate amount of alcohol is harmless; some may drink in conformance with cultural norms and beliefs. It is well known from several scientific studies that many women drink during their pregnancy simply to cope with their difficult living circumstances and relationships—to lessen their fear, anxiety, depression, and loneliness.

Not only women, but also their male partners, their social support networks, and society at large are responsible for FASD, and must also be held responsible for its prevention. At least one in every 100 babies born has to live with this permanent disability. In Canada alone, with a population of 33 million, there are about 300 000 individuals living with this injury. If the same incidence holds for the United States, with its population of 307 million, there are about three million people in that country forever incapacitated by having been exposed to alcohol during their most vulnerable time in life—their first nine months. In Europe, with a population of more than 500 million, there may be as many as five million people living with this preventable syndrome.

When thousands of babies are born every year with permanent brain injury of known cause, the response to that ought to be a forceful, determined, concerted, compassionate, sustainable and effective effort to prevent such an occurrence.

## 1.1

### **The Content of This Book**

This book presents findings from research on different strategies to prevent FASD. Although prevention of this syndrome is challenging, promising results have been obtained from many studies, demonstrating that certain prevention programs are effective in reducing alcohol use during pregnancy.

Chapters 2 and 3, which form the core of the book, are systematic reviews of a large number of studies on the prevention of FASD that have been published in the scientific literature. Chapter 2 also includes a review of the effectiveness of different strategies for diagnosis and treatment, which also are relevant in FASD prevention. Maria Ospina and colleagues have examined the strength of the evidence in each of the studies, and have found some prevention strategies that have clearly been shown to work. But, perhaps more importantly, they have also identified other programs that may not be effective.

It seems self-evident that ineffective strategies for prevention should not be used. However, the reviews show, for example, that widely used and comparatively expensive strategies—such as alcohol-related warning messages, alcohol bans, and some other social marketing strategies implemented on a massive scale—have a limited effectiveness. They do not seem to increase knowledge of FASD, nor to change attitudes toward alcohol use during pregnancy.

On the other hand, focused multimedia education programs aimed at youth in school settings show some evidence of effectiveness, as do health education programs directed at women of childbearing age and pregnant women. Some screening programs for the prenatal use of alcohol have proven effective in identifying high-risk women, and there is strong evidence of the effectiveness of several types of intervention in reducing alcohol use during pregnancy.

The most important finding from the systematic reviews may be that comparatively few FASD-prevention programs have been evaluated. Moreover, among those that have been assessed, only a small fraction have employed a rigorous

scientific methodology. The authors argue for more evaluation and for research into the broader social and systemic causes of alcohol use during pregnancy. They also point to the importance of promoting strategies for which there is empirical evidence of effectiveness.

Chapter 4 includes five presentations made at a consensus development conference on FASD. Lola Baydala, from the University of Alberta, presents strong evidence for school-based substance use-prevention programs and, in particular, for the Life Skills Training program initially developed at Cornell University. That program has been shown to be highly effective with students from different geographic regions and with different socioeconomic, racial, and ethnic backgrounds.

Robin Thurmeier from the Saskatchewan Prevention Institute reviews the evaluations of Canadian primary prevention campaigns for FASD. This review is based on an inventory of FASD primary prevention resources, which included campaigns such as “Be Safe; This is Our Baby”; “Alcohol and Pregnancy”; “Born Free”; “Mother Kangaroo”; and “With Child, Without Alcohol.” Some of these programs have been found to have had a high impact on the awareness of what FASD is, and that it is linked to alcohol use during pregnancy. However, little is known about how effective these campaigns are in promoting behavioral change. Robin concludes that a behavioral change model needs to be employed to guide the creation of materials and interventions, and she offers “Protection Motivation Theory” as one potential theoretical framework for guiding future prevention campaigns.

June Bergman, from the University of Calgary, discusses the role of primary healthcare in the prevention of FASD, and points out that primary care not only addresses a large majority of personal healthcare needs but also has numerous other dimensions. These include prevention and attention to the social determinants of health, as well as creating community capacity as needed. For example, primary care physicians could be more involved in screening for alcohol use during pregnancy; however, June points out that there are currently a number of barriers to that, such as lack of time and training, shortages of resources, and lack of access to the services of trained counselors when alcohol use is identified.

Nancy Whitney, from the University of Washington, discusses mentoring programs for mothers at risk and, specifically, the Parent–Child Assistance Program (PCAP), which is an intensive three-year home visitation program. The PCAP originated in Washington State some 20 years ago, and has since been replicated all over the United States. The program is tailor-made for each woman, many of whom live in poverty and with domestic violence and untreated mental health problems. The aim is to motivate these women to stop drinking before and during pregnancy, and to help those women who cannot stop drinking to avoid becoming pregnant by using family planning. Several assessments of the program have demonstrated that most women in the PCAP go from chaos to stability, become sober, live in permanent housing, become less dependent on social welfare, and use family planning. The program also seems highly cost-effective. The author recommends this type of intensive case-management program aimed at the highest-risk mothers in the community, along with the support of specialized

addiction treatment centers that welcome the women and their children. Unfortunately, such programs continue to be few in number, and are under enormous pressure to meet demands for their services.

Amy Salmon, from University of British Columbia, reminds us of our common assumption that healthy women have healthy babies, and underlines the importance of looking beyond biological factors and genetic endowment to support good health in women. She stresses the need to focus on the social determinants of health in the prevention of FASD. This requires attention to income and social status, social support networks, education, employment and working conditions, social environments, personal health practices, healthy child development, culture, and gender—all of which are unevenly supported in different jurisdictions. Findings from research have shown that those women who give birth to children with FASD are also most likely to have their own health and well-being compromised by addictions, depression, anxiety, high stress levels, and experiences of violence, trauma, grief, and loss. Clearly, the messages in FASD prevention must not build on shame and blame, which stigmatizes, discriminates and isolates women from exactly the kinds of care that they need. Increasing the system capacity for effective FASD prevention, focused on the root causes of alcohol use during pregnancy, requires a full recognition of women's health issues in its broadest sense.

## 1.2

### What is FASD?

The notion that alcohol consumption during pregnancy might be harmful to a developing fetus has been occasionally considered since antiquity. Seminal studies conducted in France and in the United States during the late 1960s and early 1970s brought a more concerted attention to the possibility. In both places, physicians detected a specific, recognizable pattern of physical traits that were consistent in some children who had been exposed to alcohol during gestation. David W. Smith and his group called this syndrome “fetal alcohol syndrome” (FAS) [1], even though they were not sure that alcohol was the true etiologic agent. Nevertheless, they were convinced that the syndrome's prevention included the elimination of alcohol from the embryo–fetal milieu. FAS was soon defined to include structural brain damage (or, at least, clinical evidence of significant brain dysfunction), a typical set of specific minor facial anomalies, and slower prenatal and/or postnatal growth. There was also evidence of problems in other organs, such as the skeleton, kidneys and heart, although these were considered to be associative rather than necessary for defining the syndrome.

Over time, the results of studies conducted with animals have proved that alcohol is indeed capable of producing embryonic and fetal damage (teratogenic). These studies have also shown that the mechanisms of teratogenesis are complex and multifaceted, so that a simple medical approach to blocking a pathway and reducing harm has not been forthcoming. The original human observations have also been confirmed, that the most common impact of fetal alcohol exposure is found in the brain. Those children who were first described with FAS had obvious

brain problems typified by severe structural malformations, significantly smaller heads than normal for their age and gender (microcephalus), neurologic problems such as seizures or cerebral palsy, and intellectual handicap. However, these severe manifestations of alcohol's effect were found over time to be only the most extreme examples, not the most common. It is now understood that alcohol primarily alters the microscopic structure and the neurochemistry of the brain, and that this can lead to global, diffuse problems with memory, executive function, social communication, complex learning tasks, attention and other processing dysfunctions.

Affected individuals have different degrees of challenge within and among functions. Among those children initially identified, tests of intellectual quotient (IQ) were frequently within the normal range. However, clinical findings from all measures would sum to a final common pathway of poor adaptive function in society, school and at home that could not be explained by any single deficit alone. The patterns and severity of the functional components were the same in children exposed to alcohol who had the facial and/or growth abnormalities, and those who did not. This led ultimately to the term "fetal alcohol spectrum disorder" (FASD), which was meant to include those with FAS and all those exposed to alcohol who demonstrated the neurobehavioral deficits without the more easily identifiable physical signs. The term FASD was meant to de-emphasize the importance of the physical findings in making a diagnosis, and to re-emphasize the "hidden" nature of this neurodevelopmental condition.

### 1.3

#### How Common is FASD?

The incidence and prevalence of FASD is poorly established because of the limited ability to detect the condition. This is itself a multifaceted problem. First, there is no full agreement on what term should be used to describe the level of brain structural abnormality found in FASD. Should this be called "prenatal brain damage," "prenatal traumatic brain injury," "diffuse brain dysfunction," "adaptive brain functional disorder," or something else? Without a uniformly recognized term and then a clear definition of severity, it has been difficult to propose or define a functional severity score that could appropriately be used to define who has been affected to the point of a disability. To date, the recognition of brain differences has been through a broad battery of cognition and performance measures that are not usually sensitive and therefore predictive of dysfunction until children are over four years of age (unless the patient has a more severe intellectual handicap as a component). This type of diagnosis is generally possible only through the work of specialized multidisciplinary teams that are in very short supply. Indeed, probably fewer than 2000 diagnoses can be made annually in all of Canada.

The study of newborns can detect babies with FAS based on growth abnormalities, the facial features, and the most severe forms of prenatal brain injury. Active case-finding studies conducted primarily during the 1970s and early 1980s found that the features of the full syndrome and a confirmed history of gestational alcohol exposure occurred in 1 to 3 per 1000 live births in the United States and

Europe [2]. Later studies suggested that the population of those with FASD might be 1 in 100 individuals, or more, depending on the levels of brain dysfunction and physical findings required by the researchers and the level of proof needed to establish the history of gestational alcohol exposure.

At the present time, there is no evidence that the rate of FASD has changed in Canada during the past two decades; nor do we know the rate at which individuals with FASD emigrate from and immigrate to other countries through adoption or immigration, nor if those with FASD have a higher death rate. However, assuming that 1 in 100 is a valid estimate of FASD prevalence, over 330 000 people in Canada have this condition right now. Far fewer than 20 000 of them have had a full FASD evaluation in a clinic that routinely uses the Canadian Guidelines for FASD Diagnosis. In fact, diagnostic capacity cannot keep pace with new cases, let alone deal with the backlog of older children, youth, and adults. While more active surveillance and case finding could be carried out at this time, the clinical capacity to make final diagnoses is the limiting factor in establishing the true prevalence of this condition in Canada, and elsewhere.

## 1.4

### What is the Economic Burden of FASD?

The economic burden of FASD is substantial by any measure. The total cost of the disorder in Canada in 2009 has been conservatively estimated at CAD7.6 billion, based on a prevalence of nine cases per 1000 births. This amount includes the cost of medical care, education, social and correctional services, as well as out-of-pocket costs and indirect costs due to caregivers' productivity losses. The direct cost of FASD in Canada for healthcare alone was CAD2.1 billion in 2009 (Table 1.1).

#### 1.4.1

##### Annual Cost Per Person with FASD

While the annual cost of healthcare for a person with FASD is estimated at CAD6860 (Table 1.2), the annual total of all direct and indirect costs is about CAD25 000 per person. The total lifetime cost of services per person with FASD in Canada was CAD1.8 million in 2009.

**Table 1.1** Cost of FASD in Canada, 2009.

Total annual direct and indirect costs	CAD7.6 billion
Total annual direct costs <sup>a)</sup>	CAD4.9 billion
Total annual direct cost of healthcare for people with FASD	CAD2.1 billion

- a) Includes the cost of healthcare and educational and social services, but excludes out-of-pocket costs and the cost of correctional services. Source: From Refs [3, 4] (adjusted to include all ages).

**Table 1.2** Annual costs per person with FASD, aged 0–53 years, in Canada 2009.

Cost item	CAD
Medical	6 860
Education	5 443
Social services	4 217
Out-of-pocket	2 912
Total direct costs	19 432
Indirect cost	1 481
Total direct and indirect costs	20 912
Adjusted for severity of disability, age	22 393
Adjusted for estimated cost of correctional services	25 000

Source: From Refs [3, 5–7].

**Table 1.3** Annual direct cost of selected diseases and FASD in Canada in 2009<sup>a</sup>.

Cost item	Annual cost (CAD)
Direct healthcare costs of respiratory diseases	4.8 billion
Direct healthcare costs of all forms of cancer	4.7 billion
Direct healthcare costs of FASD	2.1 billion

a) Includes cost of hospitalization, physicians, and drugs for each item.

Source: From Ref. [8] (discounted to 2009).

**Table 1.4** Direct annual cost of selected diseases and of FASD in Alberta, 2009.

Cost item	Annual cost (CAD)
Direct cost of healthcare of cardiovascular diseases (CVD)	773.8 million
Direct cost of healthcare of FASD	229.8 million
Direct cost of healthcare of type 2 diabetes	155.1 million
Direct cost of lung cancer	121.6 million

Source: From Ref. [8] (discounted to 2009).

#### 1.4.2

#### Comparing Costs

A comparison of the costs associated with FASD and those associated with other conditions and types of care at the macroeconomic level, helps to shed light on the economic magnitude of FASD. In order to put the cost of FASD into perspective, Tables 1.3 and 1.4 show the cost of FASD in relation to the costs of various forms of healthcare, selected on the basis of available data.

The total direct yearly cost of healthcare for FASD is almost half of the equivalent cost of all forms of cancer (Table 1.3). However, healthcare for FASD (CAD2.1 billion) is significantly more costly than, for example, the yearly cost of breast cancer and colon cancer, which are CAD380 million and CAD449 million, respectively. In fact, FASD requires more than twice the resources for healthcare alone as these two forms of cancer combined.

Another comparison at the macro level shows that the annual cost of FASD is significant also in relation to the cost of drugs. In the Canadian province of Alberta, for example, the total direct and indirect cost of FASD was CAD520 million in 2009, an amount equivalent to 25–30% of the cost of all pharmaceuticals used in the province that year [9]. The provincial healthcare costs of cardiovascular diseases, FASD, type 2 diabetes, and lung cancer are shown in Table 1.4.

### 1.4.3

#### **Cost of Prevention versus Cost of Inaction**

There are many competing priorities in healthcare, as in other sectors of society. Whilst it is common to place a higher priority in public policy on health conditions that have significant economic implications, the relative neglect of FASD shows that this is not always the case. While some countries or individual provinces do make considerable investments in FASD prevention, it is not known precisely how much any jurisdiction spends on FASD prevention; neither is it known precisely what the results of those investments have been.

In Canada, the provincial and territorial funding provided for all areas of activity in FASD (including, but not limited to, prevention) amounted to CAD26.8 million in 2007. Although funding may have increased in Canada during the past few years, it remains far short of the estimated CAD125.6 million required annually ([10], discounted) to ensure that all women receive the level of support necessary to assist them in abstaining from alcohol use during pregnancy. Conversely, the theoretical maximum cost savings of preventing FASD in Canada, which is equivalent to the total incremental cost of FASD, is approximately CAD2.6 billion annually.

What does it cost to leave FASD without prevention? The answer to this question is, to a certain extent, illuminated above. It can be further demonstrated by, for example, comparing the economic benefit of preventing one case of FASD with the cost of certain specific interventions in healthcare. For such a comparison, it is important to make use of the lifetime incremental cost per person with FASD, which is the added cost attributable to FASD alone, over and above the cost of healthcare, educational, social and correctional services for the general population. The lifetime incremental cost of one case of FASD is CAD742000 in Canada (at 2009 cost levels). This figure may be regarded as the theoretical maximum that could be spent on preventing one case of FASD. Looked at another way, it is the revenue that becomes available for other purposes when one case of FASD is prevented, or the opportunity cost for leaving FASD without prevention. The benefit of preventing one single case of FASD would amount to, for example, the



**Table 1.5** Opportunity cost of preventing *one case of FASD* in Canada in 2009.

Procedure	Average cost (CAD) <sup>a)</sup>	Number of procedures that could be performed by preventing one case of FASD
Repair of inguinal hernia	4 938	150
Appendectomy	5 505	135
Cesarean section	5 303	140
Hysterectomy	6 317	117
Cholecystectomy	6 985	106
Discectomy	7 601	98
Knee replacement	10 903	68
Hip replacement total and partial	13 182	56
Coronary artery bypass graft	24 966	30

a) Excluding atypical and long-stay cases.

Source: From Ref. [11] (discounted to 2009 cost level).

opportunity to repair about 150 inguinal hernias, or to perform 135 appendectomies, or 68 knee replacements, or 56 hip replacements (Table 1.5).

The above calculations and comparisons are all based on the costs of FASD, with little attention having been paid to what it would cost to *prevent* this disorder. Currently, many potential strategies have been proposed for the prevention of FASD, some of which are presented in Chapters 2 and 3 of this book.

Ideally, any assessment of programs focused on FASD prevention would include a formal cost–benefit or cost–effectiveness analysis. Preferably, this would be based on the incremental costs so that the cost of achieving each additional unit of the outcome measured could be determined.<sup>1)</sup> Such formal analyses would provide valuable information about the extent to which prevention is cost-saving, in addition to achieving its other targeted outcomes.

## 1.5 Approaches to FASD Prevention

### 1.5.1 Universal Prevention

Public health education campaigns directed towards mothers and aimed at improving infant and child health have been key features of the Canadian public health

1) In a cost–benefit analysis, both costs and benefits are expressed in monetary terms. In a cost–effectiveness analysis, the outcome is not expressed in monetary terms, but rather in, for example, lives

saved, years of lives saved, or number of cases intervened, counselled, or otherwise supported. In a so-called cost–utility analysis, the cost per quality-adjusted years of lives saved is calculated.

landscape for over 100 years. Indeed, they represent a relatively inexpensive and uncontroversial means of showing that some policy attention is being paid to health inequities [12, 13]. To date, the FASD-prevention activities most commonly undertaken by governments in Canada have been those aimed at changing an individual woman's alcohol use during pregnancy. For the most part, this has taken the form of primary prevention campaigns intended to increase public awareness of the risk posed by prenatal alcohol exposure, and urging pregnant women to abstain from drinking [14].

In Canada, most pregnant women whose pre-pregnancy drinking falls into "low-risk" patterns abstain from alcohol for the duration of their pregnancy. According to the most recent Canadian data, 11–15% of women consumed alcohol during their last pregnancy [15, 16]. In some countries, it is reportedly widely believed that drinking during pregnancy is good for the fetus. For example, a survey conducted in 1998 under the auspices of the Australia National Drug Strategy reported that 73.1% of pregnant women had consumed alcohol recently, and 17% of all pregnant respondents reported drinking at least three standard drinks when they drank [17]. A recent UK study [18] reported that, among the 83% of mothers who consumed alcohol prior to pregnancy, 54% continued to drink while they were pregnant.

Overall, both the incidence and prevalence of alcohol use in pregnancy seem to be changing. Most of this change is due to the fact that those women whose drinking patterns were low-risk to begin with are now abstaining completely. In Canada, although an overwhelming majority of women (98%) are aware that there is a link between alcohol use during pregnancy and harm to the fetus, a large fraction of women (62% in 2006) believe that a small amount of alcohol use during pregnancy is safe [19]. Confusion over the safety of small amounts of alcohol is evident in the conflicting guidance provided by health professionals and professional bodies. While Health Canada Report 2009 [20], the US Surgeon General [21], the Royal Australian and New Zealand College of Obstetricians and Gynaecologists [19], and the British Medical Association [22] have all taken a cautionary approach in advising women to abstain from alcohol completely while they are pregnant, others – such as the British Royal College of Obstetricians and Gynaecologists [23] – counsel that "... it remains the case that there is no evidence of harm from low levels of alcohol consumption, defined as no more than one or two units of alcohol once or twice a week." Moreover, rates of episodic high-volume and high-frequency drinking (often referred to as "binge drinking") among pregnant women and nonpregnant women of childbearing age have remained relatively stable [16, 21]. It is these drinking patterns that are most closely associated with the likelihood of having a child with FASD [24–26].

Primary prevention campaigns tend to be aimed either directly at women, or at those who might be in a position to influence a woman's alcohol use (such as partners, family members, friends, or the broader community). Such campaigns have been in existence since the mid-1970s; indeed, over 350 direct-messaging campaigns have been used in northwestern Canada alone since 2000 [27]. The presentations vary greatly from "soft" recommendations for having a healthy baby

to negative ads warning about the lifelong problems faced by children affected by alcohol. Awareness-raising materials that depict male partners, friends and family rarely provide direct suggestions on how these concerned persons might effectively help a woman to stop drinking, and no evaluations of the utility or success of these indirect messaging campaigns have yet been found. More often, the visual image is that of a lone pregnant woman or, in an attempt to make the message more universal, sometimes the focus is on the pregnant torso. However, such images may reinforce notions that FASD prevention is confined to the womb of an individual woman, thus negating the role of social, political, and economic conditions that so profoundly shape a woman's risk for having a child with FASD.

While these direct-messaging campaigns are extensive and expensive, few research data have been published that has evaluated their effectiveness in changing the behavior of pregnant women and their supporters. In fact, the materials raise many new questions:

- What harm may come from showing such messages to pregnant women, who might then worry about the potential injury to which their fetus has already been exposed?
- What is needed to ensure that primary prevention campaigns are effective across different communities, age groups, or economic or social circumstances?
- How can primary prevention campaigns avoid “blaming and shaming” women who drink while pregnant?
- Since drinking is legal and socially condoned, what written warnings would be most effective in helping women know when and how to stop?
- How can primary prevention campaigns account for relative risk?

In summary, both general and focused public awareness campaigns advising women of the harm of the gestational use of alcohol are common. Yet, remarkably few campaigns have been evaluated (see Chapters 2 and 3), and therefore little is known about their impacts. Without serious and sustained efforts to understand this social marketing experiment, improvements will not be possible. Epidemiological research on the prevalence of drinking during pregnancy indicates that while public education campaigns seem to have increased the awareness of FASD—and, by extension, have encouraged abstinence among those women whose drinking patterns place them at lowest risk—these campaigns alone have not been sufficient to support women in the highest-risk groups to abstain from alcohol during their pregnancies [2].

### 1.5.2

#### **Screening for Prenatal Alcohol Exposure in Obstetric Settings**

At present, two forms of screening for prenatal alcohol use are employed in obstetric settings: biomarkers (in the form of meconium testing; see below) and

maternal self-reports of alcohol use using direct or indirect questioning (which may involve the use of standardized screening instruments).

#### 1.5.2.1 Meconium Testing

Meconium testing involves screening samples of a newborn's first stool for the presence of fatty acid ethyl esters (FAEEs), which confirm exposure to alcohol during the last two trimesters of fetal development. Some advocates have suggested that a targeted implementation of meconium screening may be useful. For example, a recent study in a high-risk obstetric unit indicated that infants born in this unit had a 12-fold higher risk of screening positive for second- and third-trimester alcohol exposure than infants born in the general population of the referring community [28]. However, while an FAEE-positive screen can provide an indication that a woman was drinking alcohol during her pregnancy, a number of concerns regarding meconium testing as a tool for prevention and intervention in FASD exist. First, the predictive value of FAEE-positive meconium with regard to neurodevelopmental delays has not yet been established [29]; thus, in the absence of other evidence of compromised fetal development or neurobehavioral symptoms, an FAEE-positive screen itself cannot confirm that an infant has been negatively affected by prenatal alcohol exposure. Moreover, screening for alcohol (and other drug) use is different from all other types of newborn screening. In most cases, diagnostic tests reveal information that is not known to the patient or anyone else. In this case, the mother knows that she consumed alcohol in volume, and has decided not to reveal that information voluntarily. This may be because substance use during pregnancy is often interpreted as a form of abuse or neglect, which may trigger the apprehension of the infant by child welfare authorities [30]. Therefore, the implementation of meconium screening may have an unintended consequence of discouraging high-risk women from accessing obstetric care for fear of losing their children to foster care.

#### 1.5.2.2 Maternal Self-Reporting

Evidence suggests that women accurately and willingly describe their prenatal substance use when asked, provided that safety is assured. An accurate identification and assessment of alcohol-related pregnancy risk factors can be enhanced through the use of reliable screening tools [24]. Indeed, Chang [31] argues that the routine use of screening questionnaires in clinical practice may reduce the stigma associated with asking women about their alcohol use, and result in a more accurate and consistent evaluation (see also Ref. [32]). At present, there is no consensus in Canada on which standardized screening tools to use: each province and territory, healthcare organization, and healthcare provider uses a variety of formal and informal screening tools [33]. However, previous systematic reviews have demonstrated that using *any* standardized screening tool tends to make it more likely that pregnant women will disclose their alcohol use than when "standard care" practices are followed (which typically involve no direct questioning on alcohol use at all) [32]. While there are often concerns that fear, stigma, and shame can influence women to under-report their alcohol use, studies have shown that

“... there is no systematic tendency for women generally to understate the amount they drink during pregnancy” [34]; indeed, antenatal maternal reports of high-risk alcohol use tend to predict infant neurodevelopmental delay better than do postpartum maternal self-reports, most likely due to compromised recall [34]. Accurate maternal self-reporting can be improved by offering strong assurances of confidentiality,<sup>2)</sup> conducting the screening in a community setting, inviting women to complete a printed questionnaire rather than to undergo direct questioning, using more than one alcohol-consumption measure, and wording the questions clearly [35].

However, at least in maternity care settings, it appears that women are not asked as frequently as they should be. In addition, there are inconsistent processes across Canada for recording alcohol use in a woman’s medical chart, and for transferring this information to the child’s health records [33]. In 2007, only three Canadian provinces (British Columbia, Yukon, and Newfoundland) included questions in their prenatal records inquiring about pre-pregnancy alcohol use. Only two provinces (which use the same reporting form) included prompts to elicit additional information regarding women’s usual, pre-pregnancy alcohol consumption patterns (such as average amount of alcohol consumed per drinking session) [36]. Given that Pregnancy Risk Assessment Monitoring System (PRAMS) data show high rates of unplanned pregnancies—especially among young women who are the most likely to drink in binge patterns—this represents a missed opportunity for providing education, counseling, and referral for women who may be experiencing a pregnancy complicated by alcohol use.

### 1.5.3

#### Selective Prevention

Most selective prevention approaches to FASD combine some form of brief intervention and motivational interviewing. This approach has been best studied among women aged 18 to 44 years, who do not meet the criteria for alcohol dependency or a substance-use disorder, and among younger women who drink in binge patterns (i.e., Refs [35, 37]). For example, a randomized controlled trial (Project CHOICES) conducted in six community-based settings in the United States found that women who received a brief motivational intervention, consisting of four counseling sessions and a contraception consultation delivered over 14 weeks, significantly reduced their risk of having an alcohol-exposed pregnancy (as measured by decreased risky drinking and/or effective use of contraception) compared to women who received information only [24, 38].

- 2) It is important to note that research on maternal self-reporting has tended to involve studies with an experimental design, in which researchers were able to assure the women participating that their responses would be treated as confidential and would not be forwarded to their treating physician. This, in itself, may have mitigated the woman’s fear of possible negative reprisals resulting from her disclosure, but would significantly limit the generalizability of these findings to the clinical setting [24].

Although, the efficacy of paired brief intervention and motivational interviewing approaches in reducing alcohol-exposed pregnancies has not been extensively researched in Canadian settings, a range of initiatives has drawn on these findings to provide FASD-prevention supports to women. In British Columbia, Healthy Choices in Pregnancy (a component of the provincial government's healthy living initiative that included FASD-prevention targets) provided training to healthcare and related service providers to incorporate brief intervention and motivational interviewing into coordinated, informed, respectful responses to substance-using pregnant women.<sup>3)</sup> Similarly, the Alberta Alcohol and Drug Abuse Commission's Enhanced Services for Women has incorporated both motivational interviewing and brief intervention techniques into a wide range of resources to encourage the identification and referral of pregnant women with substance-use problems.

#### 1.5.4

##### **Indicated Prevention**

It is now abundantly clear that women who give birth to children with FASD are most often those whose own health and well-being are also significantly compromised. The lives of birth mothers of children diagnosed with FASD are frequently imbued with violence, isolation, poverty, mental ill health (including diagnosed psychiatric conditions, very high stress levels, and trauma), addictions, and lack of supportive health and social care before, during, and after their pregnancy [10, 39, 40]. Undoubtedly, the complexity of these issues demands a timely and coordinated approach to care that addresses social determinants of women's health.

Despite increasing acknowledgment that isolation and a lack of social support are common among pregnant women and mothers with substance-use problems, women who are most vulnerable to having a child with FASD often have difficulty accessing timely and supportive services for addictions treatment [41]; for parenting support [40, 42]; and support for issues related to violence and trauma [43]. While public health messaging campaigns exhort pregnant women to identify their drinking as problematic, and to seek professional help if they cannot stop drinking on their own, health systems and services are often unprepared to provide help when women seek it. More often than not, pregnant women facing concurrent problems with violence, mental health, and addictions will be shuffled between uncoordinated systems of care with competing and contradictory service mandates and access criteria. To illustrate this, women presenting to addictions services are often told that they need to get treatment for their mental health issues before they can enter addictions treatment, while mental health services often require abstinence from alcohol and (nonprescribed) drugs before women can be admitted into their care. Likewise, transition houses and other services for women experiencing violence have often been unprepared to provide service to women with untreated mental-health and substance-use problems [44, 45].

3) See [www.hcip-bc.org](http://www.hcip-bc.org) for more information.